Advertisement
Canada markets closed

  • S&P/TSX

    21,823.22
    +94.67 (+0.44%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • DOW

    38,225.66
    +322.37 (+0.85%)
     

  • CAD/USD

    0.7319
    +0.0005 (+0.07%)
     

  • CRUDE OIL

    79.14
    +0.19 (+0.24%)
     

  • Bitcoin CAD

    81,815.24
    +3,239.09 (+4.12%)
     

  • CMC Crypto 200

    1,287.12
    +16.37 (+1.29%)
     

  • GOLD FUTURES

    2,309.80
    +0.20 (+0.01%)
     

  • RUSSELL 2000

    2,016.11
    +35.88 (+1.81%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • NASDAQ futures

    17,760.50
    +110.75 (+0.63%)
     

  • VOLATILITY

    14.68
    -0.71 (-4.61%)
     

  • FTSE

    8,172.15
    +50.91 (+0.63%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6816
    -0.0001 (-0.01%)
     

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics AG
·2 min read
CRISPR Therapeutics AG
CRISPR Therapeutics AG

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Title: Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucoma
Session Type: In-Person Oral Presentation
Session Title: Ophthalmic and Auditory: Delivery Innovations
Abstract Number: 87
Location: Room 318 – 323
Session Date and Time: Wednesday, May 8, 2024, 1:30 p.m. – 3:15 p.m. ET

Abstracts will be released to the public on April 22, 2024, at 4:30 p.m. ET at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 8, 2024. A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.

ADVERTISEMENT

About CRISPR Therapeutics 
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com.  

Investor Contact: 
Susan Kim 
+1-617-307-7503 
susan.kim@crisprtx.com

Media Contact: 
Rachel Eides 
 +1-617-315-4493 
rachel.eides@crisprtx.com